Agios Pharma Files US Application For Mitapivat In PK Deficiency

• Agios Pharmaceuticals Inc (NASDAQ: AGIO) has submitted an FDA marketing application seeking approval for mitapivat to treat adults with pyruvate kinase (PK) deficiency.

• The company says, if approved, mitapivat could be the first potentially disease-modifying therapy for PK deficiency.

• The submission is based on two studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.

• A complete analysis of these data was recently presented at the European Hematology Association Virtual Congress.

• An extension study for adults with PK deficiency previously enrolled in ACTIVATE or ACTIVATE-T is ongoing and designed to evaluate the long-term safety, tolerability, and efficacy of treatment with mitapivat.

• The company remains on track to submit a marketing application in the EU in mid-2021 for mitapivat in adults with PK deficiency.

• Price Action: AGIO shares are up 0.86% at $61 on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study

• OPKO Health, Nicoya Therapeutics Ink Rayaldee Pact For Hyperparathyroidism In Greater China

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.